osimertinib
astrazeneca
['osimertinib']
neo adjuvant osimertinib. for surgically recetable pts. 27 pts . small data. 9 stage iii a . only 15 % mpr. trial did not meet primary end point . so end of road for neo adjuvant osimertinib? #asco23
Oncology care , to give or not to give chemo , data analysis , oncology pharamocovigilance , enthusiastic critic, twitts are not twists